Literature DB >> 26092916

Physician response to a medication alert system in inpatients with levodopa-treated diseases.

Marie Morris1, Allison W Willis1, Susan Searles Nielsen1, Franklin McCann1, Angela Birke1, Brad A Racette2.   

Abstract

OBJECTIVE: To evaluate the appropriateness of dopamine receptor antagonist prescriptions in hospitalized patients with dopamine-requiring diseases after implementation of an automated prescription alert system.
METHODS: We examined dopamine receptor antagonist prescriptions in hospitalized patients with dopamine-requiring diseases and physician response to an automated drug contraindication alert system at Barnes-Jewish Hospital from 2009 to 2013. A detailed review of patient medical records was performed for all alert events generated when a physician prescribed a dopamine receptor antagonist concurrently with a dopamine receptor agonist in hospitalized patients. Two movement disorders neurologists determined the appropriateness of each prescription, based on patient medical history, through consensus. Physician response to alert was compared by indication for the prescription and physician specialty.
RESULTS: Of 237 orders, 197 (83.1%) prescriptions for dopamine receptor antagonists were considered inappropriate. The prevalence of inappropriate dopamine receptor antagonist prescriptions per levodopa prescriptions was 16.10% (95% confidence interval 9.47, 22.73) in psychiatry, 7.51% (6.16, 8.86) in general medicine, 6.14% (4.49, 7.79) in the surgical specialties, and 0.85% (0.46, 1.25) in the neurologic/neurosurgical specialties. Of the inappropriate prescriptions, 146 (74.1%) were continued despite the alert. The strongest predictor of discontinuation of dopamine receptor antagonist medications was use of the medication to treat nausea or emesis (p < 0.001).
CONCLUSIONS: Despite successfully identifying instances when dopamine antagonists were prescribed to patients with dopamine-requiring diseases, the alert system modestly affected physician prescribing behavior, highlighting the need for improved education of health care providers.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26092916      PMCID: PMC4534077          DOI: 10.1212/WNL.0000000000001745

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.

Authors:  C G Goetz; L M Blasucci; S Leurgans; E J Pappert
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

2.  Overriding of drug safety alerts in computerized physician order entry.

Authors:  Heleen van der Sijs; Jos Aarts; Arnold Vulto; Marc Berg
Journal:  J Am Med Inform Assoc       Date:  2005-12-15       Impact factor: 4.497

3.  Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records.

Authors:  Shobha Phansalkar; Heleen van der Sijs; Alisha D Tucker; Amrita A Desai; Douglas S Bell; Jonathan M Teich; Blackford Middleton; David W Bates
Journal:  J Am Med Inform Assoc       Date:  2012-09-25       Impact factor: 4.497

4.  Provider and pharmacist responses to warfarin drug-drug interaction alerts: a study of healthcare downstream of CPOE alerts.

Authors:  Allison M Miller; Maureen S Boro; Nancy E Korman; J Ben Davoren
Journal:  J Am Med Inform Assoc       Date:  2011-10-28       Impact factor: 4.497

5.  Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  J M Miyasaki; K Shannon; V Voon; B Ravina; G Kleiner-Fisman; K Anderson; L M Shulman; G Gronseth; W J Weiner
Journal:  Neurology       Date:  2006-04-11       Impact factor: 9.910

6.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Authors:  Alan Breier; Virginia K Sutton; Peter D Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

7.  Increased incidence of levodopa therapy following metoclopramide use.

Authors:  J Avorn; J H Gurwitz; R L Bohn; H Mogun; M Monane; A Walker
Journal:  JAMA       Date:  1995-12-13       Impact factor: 56.272

8.  Olanzapine treatment for dopaminergic-induced hallucinations.

Authors:  William G Ondo; Joel K Levy; Kevin Dat Vuong; Christine Hunter; Joseph Jankovic
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

9.  The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.

Authors:  L Ganzini; D E Casey; W F Hoffman; A L McCall
Journal:  Arch Intern Med       Date:  1993-06-28

10.  Development of a context model to prioritize drug safety alerts in CPOE systems.

Authors:  Daniel Riedmann; Martin Jung; Werner O Hackl; Wolf Stühlinger; Heleen van der Sijs; Elske Ammenwerth
Journal:  BMC Med Inform Decis Mak       Date:  2011-05-25       Impact factor: 2.796

View more
  2 in total

1.  Interventions to minimize complications in hospitalized patients with Parkinson disease.

Authors:  Sana Aslam; Edith Simpson; Matthew Baugh; Holly Shill
Journal:  Neurol Clin Pract       Date:  2020-02

2.  Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease.

Authors:  James A G Crispo; Allison W Willis; Dylan P Thibault; Yannick Fortin; Harlen D Hays; Douglas S McNair; Lise M Bjerre; Dafna E Kohen; Santiago Perez-Lloret; Donald R Mattison; Daniel Krewski
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.